Novo Nordisk CEO to testify before Senate on weight loss drug prices
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, speaks during an interview in New York on August 10, 2022. Christopher Goodney…
Eli Lilly and company
Why Eli Lilly and Palo Alto Networks are keeping up with their competitors
Every weekday, the CNBC Investment Club with Jim Cramer publishes Homestretch, a handy evening update, just in time for the…
FTC sues drug brokers for allegedly inflating insulin prices
Federal Trade Commission (FTC) Chair Lina Khan testifies before the House Appropriations Subcommittee in the Rayburn House Office Building on…
Novartis CEO says it won't join weight-loss drug frenzy
The CEO of Novartis The Swiss pharmaceutical giant has no intention of getting into the “frenzy” of weight loss drugs,…
Roche releases more data on slimming pills and injections
Headquarters of Roche, a multinational pharmaceutical industry on December 27, 2021 in Madrid, Spain. Cristina Arias | Cover | Getty…
Race for radiopharmaceuticals intensifies as drugmakers chase Novartis
Drug makers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough. Bristol-Myers Squibb, AstraZeneca,…
Eli Lilly to increase production of weight loss, diabetes and Alzheimer's drugs
A sign with the company logo is displayed outside Eli Lilly headquarters in Indianapolis, Indiana, March 17, 2024. Scott Olson…
57 million privately insured adults are eligible to receive GLP-1
Slimming syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Image…
Eli Lilly could become the first $1 trillion healthcare stock
A sign with the company logo is displayed outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, on…
We're making nearly 300% gains on a rising pharmaceutical stock
Shortly after the opening bell, we will sell 10 shares of Eli Lilly at approximately $958 each. Following Monday's trade,…